Servier is committed to advancing innovative therapies that improve outcomes for our VA patients. Our growing portfolio features pioneering treatments such as Tibsovo for AML, cholangiocarcinoma, and MDS, along with Voranigo, a recently launched, first-in-class option for patients with low-grade glioma.